Tuberous Sclerosis Complex: a Case Study by Gamirova R.
Tuberous Sclerosis Complex: a Case Study
Rimma Gamirova1,2,3
Published online: 22 June 2018
# Springer Science+Business Media, LLC, part of Springer Nature 2018
Abstract
The article is a contribution to the international database of tuberous sclerosis case studies. As tuberous sclerosis complex
(Bourneville–Pringle disease) is a rare genetically determined polysystemic disease, each clinical case is very significant. The
first clinical symptoms of the disease usually appear immediately after birth, but they differ in significant polymorphism and
affect brain, different organs, and systems, including changes in the skin, nervous system, eyes, and inner organs. Accurate
diagnosis of tuberous sclerosis is fundamental to proper medical supervision and treatment. The article describes modern genetic
and clinical criteria of diagnosis in detail; the specificity of the clinical case and problems emerged during follow-up of the
patient, diagnostic errors, and findings. The author proves the importance of a multidisciplinary approach not only in diagnosis
but also in the treatment of tuberous sclerosis including neuropsychological approaches.
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1 Introduction
Bourneville–Pringle disease, or Bourneville disease, or tuber-
ous sclerosis (TS), or tuberous sclerosis complex (TSC), is a
rare genetically determined polysystemic disease, the primary
manifestations of which are benign tumors and lesions of the
skin and various organs, including the brain [1–3]. Patients
with tuberous sclerosis often suffer from epilepsy, mental re-
tardation, and autistic disorders. The incidence of the disease
is 1 per 10,000 newborns [4]. The development of tuberous
sclerosis is determined by two genes localized in segment 34
of the long arm of the 9th chromosome (tuberous sclerosis, 1st
type—TSC1, which codes for the hamartin protein,
сytogenetic location is in 9q34.13) and in the segment 13 of
the short arm of the 16th chromosome (tuberous sclerosis, 2nd
type—TSC2, which codes for the tuberin protein, сytogenetic
location is in 16p13.3) [5].
It is necessary to underline that in 75% of cases, it is a
spontaneous mutation; in 25%, it is a transmission by autoso-
mal dominant type of inheritance from parents [6].
There are several case studies of Bourneville–Pringle dis-
ease (O.Chtourou et al., 2005; A.Cichoń-Mikołajczyk et al.,
2006; S.Mimura et al., 2006; P.Dyrla et al., 2008; C.Sofoudis
et al., 2016) [7–11] which have scientific and practical signif-
icance, and each new case should be described in order to
create the effective paths of diagnosis, as the disease has dif-
ferent clinical manifestations (they may be associated with the
skin, nervous system, eye bulbs, heart, kidneys, liver, and
intestines, be presented in the form of developmental
disorders).
2 Materials and Methods
1. The diagnostic criteria for tuberous sclerosis have not
been updated for 15 years since the last Clinical
Consensus in 1998, and only in 2012, they were critically
analyzed and revised by the Conciliation Commission,
consisting of 79 specialists from 14 countries.
According to updated diagnostic criteria, the signs of tu-
berous sclerosis can be divided into the following:
A. Genetic diagnostic criteria
Identification of a genetic defect (mutation) of
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